Drug survival of secukinumab for psoriasis in a real-world setting

Drug survival of secukinumab for psoriasis in a real-world setting

Bibliographic Details
Main Authors:	Erica B. Lee, Mina Amin, Alexander Egeberg, Jashin J. Wu
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2019-02-01
Series:	Journal of Dermatological Treatment
Online Access:	http://dx.doi.org/10.1080/09546634.2018.1473838

Similar Items

Drug survival of guselkumab for psoriasis in a real-world setting: a single-center retrospective chart review
by: Erica B. Lee, et al.
Published: (2020-05-01)

Treatment changes in patients with psoriasis on etanercept or adalimumab: a retrospective chart review
by: Erica B. Lee, et al.
Published: (2018-10-01)

Clinical efficacy and safety of secukinumab for psoriasis in a real-world setting in Turkey
by: Fatma Elif Yıldırım, et al.
Published: (2022-04-01)

Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review
by: Erica B. Lee, et al.
Published: (2018-10-01)

Drug survival of biologic treatments in psoriasis: a systematic review
by: Daniel J. No, et al.
Published: (2018-07-01)

Long-term efficacy, safety, and drug survival of secukinumab in patients with psoriasis in Turkey: a retrospective analysis of real-world experience
by: Fatma Elif Yıldırım, et al.
Published: (2024-03-01)

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence
by: Jashin J. Wu, et al.
Published: (2020-04-01)

Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection
by: Matteo Megna, et al.
Published: (2022-07-01)

Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting
by: Bruce Strober, et al.
Published: (2022-11-01)

Secukinumab for plaque psoriasis
by: Gonzalo Ordenes-Cavieres, et al.
Published: (2018-11-01)

US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry
by: Bruce E. Strober, et al.
Published: (2020-05-01)

Review of European registries for psoriasis
by: Mina Amin, et al.
Published: (2019-04-01)

Atopic dermatitis 2017: where we were 10–15 years ago in psoriasis
by: Daniel J. No, et al.
Published: (2018-01-01)

Real-world investigation of the efficacy and safety of secukinumab for psoriasis treatment in a Chinese population
by: Jing-Xin Zeng, et al.
Published: (2021-01-01)

Psoriasis and Co-morbidity
by: Mina Amin, et al.
Published: (2020-01-01)

How to choose between IL-17 inhibitors and IL-23 inhibitors for psoriasis
by: Mina Amin, et al.
Published: (2019-05-01)

Secukinumab Therapy in Psoriasis Management
by: Ira Yunita, et al.
Published: (2022-03-01)

Secukinumab in generalized pustular psoriasis
by: Shraddha Madanagobalane
Published: (2018-01-01)

Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry
by: Martina Kojanova, et al.
Published: (2022-08-01)

Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study
by: Giannis Chatzimichail, et al.
Published: (2022-04-01)

The significance of secukinumab in the treatment of plaque psoriasis
by: Marta Kasprowicz-Furmańczyk, et al.
Published: (2022-02-01)

Review of U.S. registries for psoriasis
by: Mina Amin, et al.
Published: (2017-11-01)

No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis
by: Therezia Bokor-Billmann, et al.
Published: (2019-04-01)

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
by: Li Y, et al.
Published: (2022-10-01)

Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis
by: Logan W. Thomas, et al.
Published: (2019-02-01)

Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
by: Tzong-Yun Ger, et al.
Published: (2019-04-01)

Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials
by: Alice B. Gottlieb, et al.
Published: (2022-04-01)

Secukinumab retreatment associated psoriasis flare with pustules
by: Mohamed EL-Komy, et al.
Published: (2022-02-01)

Scalp psoriasis: report of efficient treatment with secukinumab
by: Giuseppe Pistone, et al.
Published: (2018-11-01)

Secukinumab in psoriasis: A single-center experience
by: Esra Ağaoğlu, et al.
Published: (2021-09-01)

Secukinumab-induced paradoxical palmoplantar pustular psoriasis
by: Yıldız Gürsel Ürün, et al.
Published: (2022-12-01)

Promising results with secukinumab in refractory pediatric psoriasis
by: Sukriti Baveja, et al.
Published: (2020-01-01)

Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
by: Alessio Gambardella
Published: (2019-09-01)

Profile of secukinumab in the treatment of psoriasis: current perspectives
by: Roman M, et al.
Published: (2015-12-01)

Secukinumab in the treatment of psoriasis: patient selection and perspectives
by: Yang EJ, et al.
Published: (2018-10-01)

Real-world clinical experience of secukinumab in Chinese patients with psoriasis in real-world practice: a 36-week single-center study of 24 patients
by: Jing Zhang, et al.
Published: (2020-12-01)

Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study
by: Hao Trong Nguyen, et al.
Published: (2022-12-01)

Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date
by: Kivelevitch D, et al.
Published: (2019-04-01)

Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability
by: Narbutt J, et al.
Published: (2023-02-01)

Real-world safety and effectiveness of secukinumab in adult patients with moderate to severe plaque psoriasis: results from postmarketing surveillance in Korea
by: Byung Soo Kim, et al.
Published: (2024-02-01)